Piperonyl Butoxide

CHEMBL1201131 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
338.4 g/mol
LogP
3.7
Phase
4

Piperonyl butoxide is a synergist compound that inhibits cytochrome P450 and other oxidative enzymes in insects, thereby preventing the metabolic detoxification of pyrethroid and other insecticide agents and markedly enhancing their insecticidal activity. It is widely used in combination with pyrethrins or permethrin in topical antiparasitic products for head lice, scabies, and malaria vector control.

分子量

338.4000 g/mol

LogP

3.70

TPSA

46.20 Ų

リピンスキーの五則

適合

治療領域

作用機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2

InChI

InChI=1S/C19H30O5/c1-3-5-7-20-8-9-21-10-11-22-14-17-13-19-18(23-15-24-19)12-16(17)6-4-2/h12-13H,3-11,14-15H2,1-2H3

Molecular Formula

C19H30O5

HBD / HBA

- / 5

回転可能結合数

13

重原子数

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Piperonyl butoxide is a synergist compound that inhibits cytochrome P450 and other oxidative enzymes in insects, thereby preventing the metabolic detoxification of pyrethroid and other insecticide agents and markedly enhancing their insecticidal activity. It is widely used in combination with pyrethrins or permethrin in topical antiparasitic products for head lice, scabies, and malaria vector control.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Piperonyl Butoxide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201131. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5794. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.